MedTrace Logo

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

NCT06043011 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2950

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • Waldenström's Macroglobulinemia (WM)

Interventions

OTHER

Routine care as per site standard.

Physician's choice according to patient's needs.

Sponsors & Collaborators

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Rainer Claus, Prof. Dr. · Universitätsklinikum Augsburg, Germany

  • Tobias Dechow · Studienzentrum Onkologie Ravensburg, Germany

  • Paul Graf La Rosée, Prof. Dr. · Schwarzwald-Baar Klinikum, Germany

  • Jens Kisro, Dr. · Lübecker Onkologische Schwerpunktpraxis, Germany

  • Patrick Marschner, Dr. · Praxis für Interdisziplinäre Hämatologie und Onkologie, Freiburg, Germany

  • Ingo Tamm, PD Dr. · Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany

  • Robert Zeiser, Prof. Dr. · Universitätsklinikum Freiburg, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2033-12-31
Completion
2033-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043011 on ClinicalTrials.gov